CLINICAL OUTCOMES OF HEMOPERFUSION USING HA130 AMONG END STAGE RENAL DISEASE PATIENTS ON MAINTENANCE HEMODIALYSIS IN A TERTIARY HOSPITAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/0aa46b050e2beac634db6185d4b8141a.pdf
CLINICAL OUTCOMES OF HEMOPERFUSION USING HA130 AMONG END STAGE RENAL DISEASE PATIENTS ON MAINTENANCE HEMODIALYSIS IN A TERTIARY HOSPITAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
HANIFA
SOLAIMAN
HANIFA SOLAIMAN engrHDS@gmail.com Cotabato Regional Medical Center Internal Medicine Cotabato Philippines *
LINTANG BEDOL JR. jrbedol@gmail.com Cotabato Regional Medical Center Internal Medicine Cotabato Philippines -
-
-
-
-
-
-
-
-
-
-
-
-
-

End-stage renal disease (ESRD) patients on maintenance hemodialysis (HD) often experience high morbidity and symptom burden due to inadequate clearance of middle molecules, which conventional HD cannot effectively remove. Hemoperfusion (HP) using the HA130 cartridge has emerged as an adjunct therapy designed to enhance toxin removal and improve clinical outcomes. This study aimed to evaluate the clinical and laboratory outcomes of ESRD patients on maintenance HD undergoing adjunctive hemoperfusion with the HA130 cartridge. 

This retrospective cohort study reviewed 19 patients from November 2024 to August 2025. Clinical outcomes were measured at baseline, 1 month, and 3 months. Patient-reported outcomes included pruritus, sleep, appetite, and satisfaction. Laboratory parameters included serum creatinine, phosphorus, calcium, hemoglobin, and albumin. Statistical analyses used Wilcoxon signed-rank tests and ANOVA.

Significant reductions were observed in pruritus score (mean score reduced from 3.26 to 0.26; p < 0.001) and improvements in sleep duration (2.53 ± 0.61 hours to 5.42 ± 0.51 hours; p < 0.001). Serum phosphorus decreased significantly from 2.88 ± 0.88 mmol/L to 2.29 ± 0.56 mmol/L (p = 0.045). No significant changes were noted in hemoglobin and platelet count, indicating hematologic stability. Other laboratory markers remained stable without adverse metabolic effects. 

Adjunctive HA130 hemoperfusion was safe and associated with improved uremic symptoms and phosphate control in ESRD patients while preserving baseline hematologic indices.

Kewords